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: IMPROVED PROCESS FOR THE PREPARATION OF UPADACITINIB AND ITS INTE

IMPROVED PROCESS FOR THE PREPARATION OF UPADACITINIB AND ITS
INTERMEDIATES

The present invention relates to an improved process for the preparation of (3S,4R)-35

Ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1carboxamide formula (1).

The present invention also relates to an improved process for the preparation of
formula (6), which is used as an intermediate in the preparation of (3S,4R)-3-Ethyl-4-(3H10

imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide
of formula (1).

The compound of formula (1) commonly known as “Upadacitinib” and it is a Janus
kinase (JAK) inhibitor indicated for the treatment of adults with moderately to severely
15

active rheumatoid arthritis who have had an inadequate response or intolerance to
methotrexate, and it is approved by USFDA under brand name of RINVOQ™.
US 8426411B2 (hereinafter referred as US ‘411) discloses a process for preparation
of Upadacitinib as shown in below.
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The above prior art process suffered with few draw backs. Such as use of NaH highly
inflammable and more number of stages. Hence this is not safe & not viable at commercial
5

scale-up.
PCT application, WO 2017066775A1 discloses processes for the preparation of
Upadacitinib as shown in below.

2
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The main drawback of the above process is expansive, more number of steps for
additional deprotection.
In view of the above, inventors of the present invention developed an improved
process for the preparation of Upadacitinib which is circumvent the above describes
5

problems.

Advantages of the present invention:

10



Cyclisation and deprotection in a single step without using any deprotecting agent.



Cost-effective process with less number of stages.

Brief description of the invention
In first embodiment, the present invention provides an improved process for the
preparation of Upadacitinib.

Detailed description of the invention
15

The term "Solvent" used in the present invention refers to "hydrocarbon solvents"
such as n-hexane, n-heptane, cyclohexane, petroleum ether, benzene, toluene, xylene and the
like; "ether solvents" such as dimethyl ether, diisopropyl ether, diethyl ether, methyl tertbutyl ether, 1,2-dimethoxy ethane, tetrahydrofuran, Trifluoroacetic anhydride, 1,4-dioxane
and the like; "ester solvents" such as methyl acetate, ethyl acetate, isopropyl acetate, n-butyl

20

acetate, isobutyl acetate and the like; "polar-aprotic solvents such as dimethylacetamide,
dimethylformamide, dimethylsulfoxide, N-methylpyrrolidone and the like; "chloro solvents"
such as dichloromethane, dichloroethane, chloroform, carbon tetrachloride and the like;
"ketone solvents" such as acetone, methyl ethyl ketone, methyl isobutyl ketone and the like;
"nitrile solvents" such as acetonitrile, propionitrile, isobutyronitrile and the like; “alcohol

25

solvents” such as methanol, ethanol, n- propanol, isopropanol, n-butanol, isobutanol, tbutanol, n-pentanol, isopentanol, 2-nitroethanol, ethylene glycol, 2-methoxyethanol, l, 2ethoxyethanol, diethylene glycol, 1, 2, or 3-pentanol, neo-pentyl alcohol, t-pentyl alcohol,
diethylene glycol monoethyl ether, benzyl alcohol, phenol, or glycerol and the like; “polaraprotic solvents" such as dimethylacetamide (DMA), dimethylformamide (DMF),
3
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dimethylsulfoxide (DMSO), N-methylpyrrolidone (NMP) and the like; "polar solvents" such
as water or mixtures thereof.
As used herein the present invention, the term “base” is selected from inorganic bases
like “alkali metal hydroxides” such as lithium hydroxide, sodium hydroxide, potassium
5

hydroxide and the like, “alkali metal carbonates” such as caesium carbonate, sodium
carbonate, potassium carbonate, lithium carbonate, rubidium carbonate and the like; “alkali
metal hydrides” such as sodium hydride, potassium hydride, lithium hydride and the like;
ammonia; and organic bases such as triethyl amine, methyl amine, ethyl amine,
diisopropylethylamine; “alkali metal alkoxides” such as sodium methoxide, sodium ethoxide,

10

sodium tert-butoxide, potassium ethoxide, potassium tert-butoxide thereof.
In first embodiment, the present invention provides an improved process for the
preparation of Upadacitinib, comprising:
a) reacting the compound of general formula (6) with the compound general formula (5)
in presence of a base in a solvent to get compound of general formula (4),

15
b) removing the Boc protecting group of compound of general formula (4) to get a
compound of formula (3),

20

c) cyclizing the compound of formula (3) in presence of an acid source & a base to get
8-((3R,4S)-4-ethylpyrrolidin-3-yl)-3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazine (formula
(2)),

4
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d) converting the compound of 8-((3R,4S)-4-ethylpyrrolidin-3-yl)-3H-imidazo [1,2a]pyrrolo[2,3-e]pyrazine(formula (2)) to Upadacitinib.
wherein, X refers to a leaving group selected from halogen group such as Cl, Br, I, F,
5

MsCl, TsCl and the like thereof.
wherein, Pg refers to a protecting group such as carbobenzyloxy (Cbz), benzoyl (Bz),
benzyl (Bn), tosyl (Ts), p-methoxybenzyl carbonyl (Moz or MeOZ), tert-butyloxycarbonyl
(BOC), acetyl (Ac), carbamate, p-methoxybenzyl, 3,4-dimethoxybenzyl, p-methoxyphenyl
(PMP), trichloroethyl chloroformate, nosyl and the like thereof.

10

The solvent is used in step-a) to step-c) selected from ketone solvents such as acetone,
methyl ethyl ketone, methyl isobutyl ketone and the like; nitrile solvents such as acetonitrile,
propionitrile, isobutyronitrile and the like; alcohol solvents such as methanol, ethanol, npropanol, isopropanol, n-butanol, isobutanol, t-butanol and the like; ester solvents such as
methyl acetate, ethyl acetate, isopropyl acetate, n-butyl acetate, isobutyl acetate and the like;

15

ether solvents such as dimethyl ether, diisopropyl ether, diethyl ether, methyl tert-butyl ether,
1,2-dimethoxy ethane, tetrahydrofuran, Trifluoroacetic anhydride, 1,4-dioxane and the like;
"chloro solvents" such as dichloromethane, dichloroethane, chloroform, carbon tetrachloride
and the like;
The acid source used in step c) is selected from organic or inorganic acids such as

20

acetic anhydride, toluenesulfonic acid, methanesulfonic acid, perfluoro acid anhydrides
include trifluoroacetic anhydride, pentafluoropropionic anhydride, heptafluorobutyric
anhydride, and combinations thereof, wherein the acid source used in step c) is ranging
between 5-30 equivalents. Preferably, 15-20 equivalents.
The “base” used in step-a) to step-c) is selected from organic or inorganic bases such

25

as sodium hydroxide, potassium hydroxide, cesium carbonate, sodium carbonate, potassium
5
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carbonate, lithium carbonate, rubidium carbonate, pyridine and the like, wherein base used in
step c) is the ranging between 4-30 equivalents. Preferably, 15-20 equivalents.
In first aspect of first embodiment, the present invention provides an improved
process for the preparation of Upadacitinib, comprising:
5

a) reacting the 2-bromo-1-((3S,4R)-4-ethyl-1-tosylpyrrolidin-3-yl)ethanone formula (6a)
with tert-butyl (5-tosyl-5H-pyrrolo[2,3-b]pyrazin-2-yl)carbamate formula (5a) in
presence of a base in a solvent to get tert-butyl (2-((3R,4S)-4-ethyl-1-tosylpyrrolidin3-yl)-2-oxoethyl)(5-tosyl-5H-pyrrolo[2,3-b]pyrazin-2-yl)carbamate formula (4a),

10

b) removing the Boc protecting group from tert-butyl (2-((3R,4S)-4-ethyl-1tosylpyrrolidin-3-yl)-2-oxoethyl)(5-tosyl-5H-pyrrolo[2,3-b]pyrazin-2-yl)carbamate
formula

(4a)

to

get

1-((3R,4S)-4-ethyl-1-tosylpyrrolidin-3-yl)-2-((5-tosyl-5H-

pyrrolo[2,3-b]pyrazin-2-yl)amino)ethanone formula (3a),

15

c) cyclizing the 1-((3R,4S)-4-ethyl-1-tosylpyrrolidin-3-yl)-2-((5-tosyl-5H-pyrrolo[2,3b]pyrazin-2-yl)amino)ethanone formula (3a) in presence of an acid source & a base to
get

8-((3R,4S)-4-ethylpyrrolidin-3-yl)-3H-imidazo

[1,2-a]pyrrolo[2,3-e]pyrazine

formula (2),

6
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d) converting the compound of 8-((3R,4S)-4-ethylpyrrolidin-3-yl)-3H-imidazo [1,2a]pyrrolo[2,3-e]pyrazine formula (2) to get Upadacitinib.

In second aspect of the first embodiment, the present invention provides an process
5

for the preparation of formula-3a, comprising:
a) reacting the 2-bromo-1-((3S,4R)-4-ethyl-1-tosylpyrrolidin-3-yl)ethanone formula
(6a) with tert-butyl (5-tosyl-5H-pyrrolo[2,3-b]pyrazin-2-yl)carbamate formula
(5a) to get tert-butyl (2-((3R,4S)-4-ethyl-1-tosyl pyrrolidin-3-yl)-2-oxoethyl) (5tosyl-5H-pyrrolo[2,3-b]pyrazin-2-yl) carbamate formula (4a),

10
b) removing the Boc protecting group from tert-butyl (2-((3R,4S)-4-ethyl-1-tosyl
pyrrolidin-3-yl)-2-oxoethyl)(5-tosyl-5H-pyrrolo[2,3-b]pyrazin-2-yl)carbamate
formula (4a) to get 1-((3R,4S)-4-ethyl-1-tosylpyrrolidin-3-yl)-2-((5-tosyl-5Hpyrrolo[2,3-b]pyrazin-2-yl)amino)ethanone formula (3a),

15
In second embodiment, the present invention provides a novel process for the
preparation of Upadacitinib, comprising:
a) reacting the compound formula (10) with compound formula (9) in presence of a base
20

in a solvent to get compound of formula (8),

7
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b) removing the Boc protecting group from compound of formula (8) to get compound
formula (7),

5
c) cyclizing the compound formula (7) in presence an acid source & base to get
Upadacitinib of formula (1),

10

In third embodiment, the present invention provides an improved process for
preparation of formula (6), comprising:
a) converting the compound of formula (14) to formula (13)

b) treating the compound of formula (13) with protecting agent to get compound of
15

formula (12).
8
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wherein, P refers to a hydrogen or protecting group such as carbobenzyloxy (Cbz),
benzoyl (Bz), benzyl (Bn), tosyl (Ts), p-methoxybenzyl carbonyl (Moz or MeOZ), tertbutyloxycarbonyl
5

(BOC),

acetyl

(Ac),

carbamate,

p-methoxybenzyl,

3,4-

dimethoxybenzyl, p-methoxyphenyl (PMP), trichloroethyl chloroformate, nosyl and the
like thereof.
c) converting the compound of formula (12) using oxidizing agent to obtain compound
of formula (11).

10

wherein, P refers to as same as defined herein before.
where in, oxidizing agent is selected from TEMPO, chromic acid such as chromium
trioxide, potassium dichromate, sodium dichromate, pyridinium chlorochromate, PCC.
Chromic acid and the like;
d) converting the compound of formula (11) to (3R, 4S)-tert-butyl 3-(2-bromoacetyl)-4-

15

ethylpyrrolidine-1-carboxylate of formula (6).

In fourth embodiment, the present invention provides 1-((3R,4S)-4-ethyl-1tosylpyrrolidin-3-yl)

-2-((5-tosyl-5H-pyrrolo

[2,3-b]pyrazin-2-yl)amino)ethanone

of

compound of formula (3a).
20

9
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In fifth embodiment, the present invention provides tert-butyl (2-((3R,4S)-4-ethyl-1tosylpyrrolidin-3-yl)-2-oxoethyl)(5-tosyl-5H-pyrrolo[2,3-b]pyrazin-2-yl)carbamate

of

formula (4a).

5
Wherein Formula-2, Formula-2a, Formula-3 or formula-3a to Upadacitinib can be
carried out by the methods known in the prior art.
In another embodiment, Upadacitinib obtained by the present invention is used for the
10

preparation of various pharmaceutical compositions formulated in a manner suitable for the
route of administration to be used where at least a portion of compound of Formula-I is
present in the composition in particular solid form mentioned.
In yet another embodiment, the present invention also encompasses pharmaceutical
compositions comprising Upadacitinib of formula-1 of the present invention. As used herein,

15

the term "pharmaceutical compositions" or "pharmaceutical formulations" include tablets,
pills, powders, liquids, suspensions, emulsions, granules, capsules, suppositories, or injection
preparations.
The process described in the present invention was demonstrated in examples
illustrated below. These examples are provided as illustration only and therefore should not

20

be construed as limitation of the scope of the invention:

10
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Examples
Example 1: Preparation of tert-butyl (2-((3R,4S)-4-ethyl-1-tosylpyrrolidin-3-yl)-2oxoethyl) (5-tosyl-5H-pyrrolo[2,3-b]pyrazin-2-yl)carbamate formula (4a).
Tert-butyl (5-tosyl-5H-pyrrolo[2,3-b]pyrazin-2-yl)carbamate (0.4 gr) of formula (5a)
5

was added to Dimethylacetamide (3.2 ml) and tetrahydrofuran (0.8 ml) at 25 ±5°C and stirred
for 1 hour. Cooled the reaction mixture to -30 ±5°C. Added cesium carbonate (1.0 gr) and 2bromo-1-((3R,4S)-4-ethyl-1-tosylpyrrolidin-3-yl)ethanone (0.77 gr) of formula (6a) to the
reaction mixture and stirred for 8-10 hours at same temperature. Quenched reaction mixture
with water (10.0 vol), ethyl acetate (10.0 vol) and stirred for 10 min. Separated both layers

10

and distilled off the solvent from the organic layer to obtain the title compound (Yield: 0.47
gr).

Example 2: Preparation of 1-((3R,4S)-4-ethyl-1-tosylpyrrolidin-3-yl)-2-((5-tosyl-5Hpyrrolo[2,3-b]pyrazin-2-yl)amino)ethanone formula (3a).
15

Tert-butyl

(2-((3R,4S)-4-ethyl-1-tosylpyrrolidin-3-yl)-2-oxoethyl)

(5-tosyl-5H-

pyrrolo[2,3-b]pyrazin-2-yl)carbamate (0.4 gr) of formula (4a) obtained in Example-1 was
added to dichloromethane (4.0 ml) and trifluoroacetic acid (0.40 gr) at 30 ±5°C. Heated the
reaction mixture to 40 ±5°C and stirred for 4-5 hours. Cooled the reaction mixture to 30
±5°C. Added water (4.0 ml) and aq sodium bicarbonate (4.0 ml) solution to reaction mixture.
20

Separated both layers and distilled off the solvent from the organic layer to obtain the title
compound (Yield: 0.29 gr).

Example-3: Preparation of diethyl 2-propylidenemalonate.
Diethyl malonate (200 gr) was added to dimethylformamide (400 ml) and
25

cyclohexane (400 ml) at 25 to 30°C. Acetic acid (75 gr) was added to the reaction mixture,
added Piperidine (106.25 gr) and stirred for 10 min and temperature slightly goes up to the
40 ±5°C. Added propionaldehyde (108.9 gr) to the reaction mixture at same temperature and
stirred for 30 min. Cooled the reaction mixture to 25 ±5°C. Settled and separated
cyclohexane layer. Added water, sodium chloride and cyclohexane to the DMF layer and

30

stirred for 10min.Settled and separated aqueous layer and organic layer. Aq layer was
11
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extracted with cyclohexane. Combined organic layers and cooled to 0 ±5°C. Washed the
organic layer with conc HCl solution at same temperature and followed by washed with aq
sodium chloride solution. Dried organic layer with sodium sulfate. Distilled off the solvent
from organic layer to obtain the residue and then purified by coloumn chromatography (using
5

20% ethyl acetate in cyclohexane as eluents) to get title compound (120 gr).

Example-4: Preparation of diethyl 2-(1-nitrobutan-2-yl)malonate.
Dissolved diethyl 2-propylidenemalonate (120 gr) in toluene (600 ml) at 25±5°C.
Cooled the mixture to 10 ±5°C. DBU (22.6 gr), nitro methane (60 gr) were added to the
10

above mixture and stirred for 1 hour at 25±5°C. Raised the temperature of the reaction
mixture to 25 ±5°C and stirred for 1 hour. Cooled the reaction mixture to 0 ±5°C. Washed the
reaction mixture with aqueous HCl solution and aqueous sodium bicarbonate solution.
Distilled off the solvent from the organic layer to get title compound (Yield: 148 gr).

15

Example-5: Preparation of ethyl 4-ethyl-2-oxopyrrolidine-3-carboxylate.
Diethyl 2-(1-nitrobutan-2-yl)malonate (80 gr) was dissolved in methanol (500 ml) at
25 ±5°C. Added 10% Pd/C (7.0 gr) to the mixture at same temperature and applied H2
pressure stirred for 20 min. Raised the temperature of the reaction mixture to 40 ±5°C and
stirred for 15 to 20 hours. Cooled the reaction mixture to 25 ±5°C and filtered through

20

hyflow bed to remove catalyst. Washed filtrate with methanol (100 ml) distilled off the
solvent under vacuum at 45 ±5°C to get titled compound (Yield: 57 gr).

25

Example-6: Preparation of ethyl 4-ethyl-2-oxopyrrolidine-3-carboxylate (alternate
process).
Diethyl 2-(1-nitrobutan-2-yl)malonate (148 gr) was dissolved in methanol (740 ml) at
25 ±5°C. Added 10% Pd/C (12.0 gr) to the mixture at same temperature stirred under 5kg of
H2 pressure at 30±5°C for 24 hours. Filtered the reaction mixture under the nitrogen
atmosphere and distilled off solvent under reduced pressure and degassing for 10min at 2530°C. Added chloroform to the obtained compound. Washed mixture with 10% citric acid

30

solution. Concentrate the organic layer under reduced pressure to get titled compound (Yield:
82 gr).
12

https://www.tdcommons.org/dpubs_series/5269

13

